The envelope protein (gp120) of human immunodeficiency virus (HIV) contains highly conserved mannosylated oligosaccharides. These glycoconjugates contribute to resistance to antibody neutralization, and binding to cell surface lectins on macrophages and dendritic cells. Mannose-binding lectin (MBL) binds to gp120 and plays a role in defence against the virus. In this study it is demonstrated that surfactant protein D (SP-D) binds to gp120 and inhibits HIV infectivity at significantly lower concentrations than MBL. The binding of SP-D was mediated by its calcium-dependent carbohydrate-binding activity and was dependent on glycosylation of gp120. Native dodecameric SP-D bound to HIV gp120 more strongly than native trimeric SP-D. Since one common polymorphic form of SP-D is predominantly expressed as trimers and associated with lower blood levels, these individuals may have less effective innate defence against HIV. A chimeric protein containing the N-terminal and collagen domains of SP-D linked to the neck and carbohydrate-recognition domains of MBL (called SP-D/MBL neck+CRD ) had greater ability to bind to gp120 and inhibit virus replication than either SP-D or MBL. The enhanced binding of SP-D/MBL neck+CRD was dependent on assembly into higher molecular mass multimers (i.e. a trimeric form of the chimera did not bind to a greater extent than MBL). Hence, the enhanced binding of SP-D compared with MBL results from distinctive properties of its N-terminal and/or collagen domains. SP-D is present in lung and airway fluids, as well as in blood and various mucosal locations, and could, like MBL, play a role in restricting HIV transmission or replication in vivo.
INTRODUCTION
Glycosylation of the human immunodeficiency virus (HIV) envelope protein, gp120, plays an important role in the pathogenesis of the acquired immunodeficiency syndrome (AIDS). gp120 is very highly glycosylated with 24 utilized N-linked glycosylation sites on the well characterized HIV-1 LAI strain (Leonard et al., 1990) . gp120 has a particularly high proportion of high mannose oligosaccharide attachments, and the high mannose and hybrid oligosaccharides are conserved among different viral isolates (Sanders et al., 2002) . In addition to possible roles of these glycans in the synthesis and folding of gp120 during assembly, important interactions with the immune system have been established.
Recent studies indicate that gp120-associated glycans are modified among sequential isolates of HIV taken at different time points after infection in individual subjects (Wei et al., 2003) . These modifications are associated with evolving resistance to antibody neutralization. These findings have given rise to the concept that gp120 remains resistant to antibody neutralization by use of a 'glycan shield', a protective coat of oligosaccharides that inhibits antibody binding to gp120 without blocking sites critical for binding to cellular receptors. A survey of sera from HIV-infected subjects showed a lack of effective neutralizing antibodies directed against carbohydrate epitopes on gp120 (Wei et al., 2003) . One illustrative exception is a broadly neutralizing monoclonal antibody, 2G12, that recognizes a specific constellation of high mannose oligosaccharides on the protein (Sanders et al., 2002) . Of interest, the high mannose oligosaccharides recognized by 2G12 are clustered on the end of gp120 most distal from the viral envelope and adjacent to the cell-binding domain of the molecule. These glycans are, therefore, highly accessible to binding by soluble or cell surface lectins or other ligands.
Mannosylated oligosaccharides on gp120 also are involved in the binding of HIV to the DC-SIGN lectin or homologous C-type lectin, langerin, expressed on the surface of dendritic cells and Langerhan's cells, respectively (Hong et al., 2002; Lue et al., 2002; Turville et al., 2003) . Dendritic cell lectins appear to play an important role during initial infection with HIV. This receptor allows immature dendritic cells to bind HIV in mucosal locations (e.g. the vaginal mucosa) such that these cells then transmit the virus in viable form to lymphoid rich areas where T cells be infected (Turville et al., 2002) . Mannosylated glycans also mediate uptake of the virus by macrophages via the macrophage mannose receptor that also allows transmission of the infection to T cells (Nguyen & Hildreth, 2003) .
High mannose oligosaccharides on gp120 also represent a potential target for inhibition by antiviral agents, like the high mannose oligosaccharide-binding agent cyanovirin (Hong et al., 2002) . Furthermore, mannose-binding lectin (MBL), a member of the collectin family of innate immune proteins, appears to contribute to host defence against HIV through a mechanism that involves binding to high mannose oligosaccharides on gp120 (Ezekowitz et al., 1989; van de Wetering et al., 2004) . A recent study also demonstrated that MBL can inhibit DC-SIGN-mediated transfer of infectious HIV from dendritic cells to T cells . Subjects having low blood levels of MBL due to polymorphic variations in the coding or promoter sequences of the protein have been found to have increased susceptibility to HIV infection in case-control studies (Boniotto et al., 2000; Garred et al., 1997; Pastinen et al., 1998) . Variant forms of MBL have also been associated with vertical transmission of HIV (Boniotto et al., 2000) . Whether low levels of MBL are associated with higher rates of disease progression or mortality after infection is controversial; some studies find an association (Garred et al., 1997) and others do not (McBride et al., 1998) .
MBL binds to primary and highly passaged isolates of HIV via mannosylated carbohydrates on gp120 (Ezekowitz et al., 1989; Hart et al., 2003; Saifuddin et al., 2000) . MBL neutralizes HIV in vitro, although the concentrations of MBL needed for neutralization are high (e.g. 20-50 mg ml 21 ) (Ezekowitz et al., 1989; Hart et al., 2003) . Removal of sialic acid from the viral surface not only increased infectivity of simian immunodeficiency virus (SIV) (Means & Desrosiers, 2000) , but also increased susceptibility of HIV to neutralization by MBL (Hart et al., 2003) . Removal of terminal sialic acids from complex oligosaccharides may facilitate viral binding by reducing negative charge, and/or increasing accessibility of high mannose or hybrid oligosaccharides.
Glycosylation of gp120 appears, therefore, to play a pivotal role in mediating interactions of the virus with innate and adaptive components of the immune system. Although mannosylated glycans on HIV are highly conserved, and therefore presumably advantageous to the virus overall, they render the virus susceptible to inhibition by collectins and (apparently rare) glycan-specific antibodies. Recent studies have shown that another member of the collectin family, surfactant protein D (SP-D), is present not only in the lung, but also in various mucosal locations (Madsen et al., 2000) and in blood (Husby et al., 2002) , where it could interact with HIV. Importantly, SP-D, unlike MBL, is expressed in locations like the genito-urinary tract, oral cavity and gastrointestinal tract (Madsen et al., 2000) , where it could impede transmission of HIV. Furthermore, alveolar macrophages are an important site of HIV replication in advanced HIV disease, and replication in the lung becomes particularly pronounced in the presence of opportunistic infection (e.g. tuberculosis) (Hoshino et al., 2002; Nakata et al., 1997) . Hence, SP-D could have important interactions with HIV in the lung itself. SP-D has been shown to play an important role in innate defence against influenza virus and respiratory syncitial virus infection Hickling et al., 1999; LeVine et al., 2001) . Polymorphisms of SP-D exist and affect susceptibility to some infections (Floros et al., 2000; Lahti et al., 2002) . Recent studies have shown that serum levels and the extent of multimerization of SP-D vary depending on SP-D genotype as well (Husby et al., 2002; Leth-Larsen et al., 2005) . In this study, we demonstrate that SP-D binds to gp120 and inhibits virus replication in culture with greater potency than MBL. The mechanism of this enhanced inhibition is also elucidated.
METHODS
Buffers. Dulbecco's PBS with calcium and magnesium was purchased from Gibco-BRL.
HIV envelope proteins. The HIV envelope protein preparations were provided by the NIH AIDS research and reference reagent programme (www.aidsreagent.org). Three purified gp120 preparations were used: HIV BAL gp120 recombinant (called 'HIV BAL ' hereafter), HIV-1 SF2162 gp120 (called 'HIV SF2 ' hereafter), and a nonglycosylated from of HIV-1 SF2 gp120 (called 'HIV SF2deglyc ' hereafter). The HIV SF2deglyc preparation was also obtained from Chiron Corporation (Emeryville, CA, USA) as a gift after it was no longer provided by the NIH AIDS research and reference reagent programme. HIV BAL is a recombinant protein produced in HEK293 cells; it was purified by immunoaffinity chromatography and was derived from a macrophagetropic viral strain. HIV SF2 was prepared in CHO cells and was also derived from a macrophage-tropic strain of HIV. The endotoxin level of this protein is 26?7 U endotoxin ml 21 and the protein was diluted 100-fold for use in ELISA (hence giving a 0?267 U endotoxin ml 21 working dilution). HIV BAL and HIV SF2 were both produced in mammalian cells, and hence have mammalian N-linked glycosylation. HIV SF2nonglyc is a nonglycosylated form of HIV SF2 produced in the yeast strain 2150; it elicits neutralizing antibodies in animals effective against HIV SF2 (Haigwood et al., 1992 Glycan blotting of the gp120 preparations was carried out using the DIG-glycan differentiation kit (Roche Diagnostics), according to the manufacturer's specifications. In brief, the gp120 preparations were subjected to SDS-PAGE under reducing conditions and transferred to PVDF membranes. A positive control (carboxypeptidase Y, 63 kDa) was included. Presence of high mannose sugars was detected with the Galanthus nivalis agglutinin (GNA) coupled to digoxigenin.
Virus preparations. HIV LAI strain was used in the infectivity experiments. The virus preparation was propagated in stimulated peripheral blood mononuclear cells from an HIV negative donor, and stored at a concentration of 10 5 particles ml 21 at 280 uC until use. Influenza A virus (IAV) (Philippines 82/H3N2 strain) was grown in chicken eggs and purified by sucrose density gradients as described previously (Hartshorn et al., 1988) .
Collectin preparations. Recombinant human SP-D (RhSP-D) and SP-D/MBL neck+CRD chimera were produced in CHO-K1 cells as previously described (Hartshorn et al., 1996a) . The SP-D/MBL neck+CRD chimera was prepared by recombinant splicing of the neck domain and carbohydrate recognition domain (CRD) of MBL onto the N-terminus and collagen domain of human SP-D . The chimera forms trimers, dodecamers and high molecular mass multimers in a manner similar to RhSP-D (White et al., 2001) . The chimera has a higher affinity for mannose than wild-type RhSP-D, and has increased ability to bind to, aggregate and neutralize IAV compared to either wild-type SP-D or MBL. For most experiments, the dodecameric RhSP-D and SP-D/MBL neck+CRD were used. However, to assess the role of collectin multimerization in the binding to HIV gp120 trimers, dodecamers and higher molecular mass multimers of SP-D/MBL neck+CRD were compared. The mode of purification of these fractions of RhSP-D or SP-D/MBL neck+CRD has been previously described in detail (Hartshorn et al., 1996a; White et al., 2000 White et al., , 2001 . Recombinant human MBL (RhMBL) was produced in murine Sp2 cells (Hartshorn et al., 1993; Super et al., 1992) . RhMBL was kindly provided by Dr Kazue Takahashi and Dr R. A. B. Ezekowitz (Department of Pediatrics, Harvard Medical School, Boston, MA, USA). This RhMBL was the more common allelic variant (termed MBP G ), and the preparation is composed predominantly of multimers containing five or six trimers (i.e. octadecamers) in association (Super et al., 1992) .
Native human SP-D and SP-A were also tested. Native human SP-D was isolated from amniotic fluid (Leth-Larsen et al., 2005; Strong & Kishore, 1998) using maltose affinity chromatography. Gel filtration chromatography was used to separate trimeric and more highly multimerized (mainly dodecameric) forms (Hartshorn et al., 1996a) .
The collectin preparations were tested for endotoxin contamination using a quantitative endotoxin assay (Limulus amebocyte lysate; Cambrex). The final concentrations of endotoxin in samples containing the highest concentrations of collectins were~20-100 pg ml 21 (or 6-12 U endotoxin ml 21 using an internal assay standard).
Assessment of the binding of collectins to HIV envelope proteins. The binding of collectins to envelope proteins was measured by ELISA. The envelope proteins were diluted to 20 mg ml 21 and allowed to adhere to ELISA plates overnight at 4 uC. The plates were then centrifuged at 2500 r.p.m. and fixed by brief incubation with 95 % ethanol, followed by 10 min incubation with methanol. The plates were then dried for 30 min. at 37 uC and incubated with PBS containing 2?5 % fatty-acid-free BSA (Sigma) for 2 h to block nonspecific binding. After washing, the plates were incubated with various concentrations of biotinylated collectins. Biotinylation of recombinant collectins has been previously described . Background binding was determined using wells coated with BSA only (see Fig. 3 ). Wells coated with IAV were used as a positive control. The binding of the HIV SF2deglyc preparation to ELISA plates was confirmed by a separate ELISA using an goat polyclonal antibody raised against the protein [provided by the NIH AIDS research and reference reagent programme (www.aidsreagent. org)]. Maximal binding was seen at 2 mg ml 21 , and a concentration of 20 mg ml 21 was used in the assay to assure maximal coating.
The binding of the recombinant collectins was also assessed using an alternative method in which unlabelled collectins were detected using mAbs. RhMBL or SP-D/MBL neck+CRD were detected using the 131-1 mAb (a gift from R. A. B. Ezekowitz) that recognizes the CRD of SP-D/MBL was detected using the 246-01 mAb. These experiments gave overall similar results to those obtained with biotinylated collectins. The binding of native SP-D to HIV envelope proteins was determined in the same manner except that the proteins were not biotinylated and detection of bound SP-D was made using a rabbit polyclonal antibody to SP-D as described (Leth-Larsen et al., 2005) .
Assessment of the effect of collectins on replication of HIV.
The ability of collectins to inhibit HIV replication was tested using U937 cells (ATCC) (Callahan et al., 2003; Hammer et al., 1986; Hartshorn et al., 1987; Zhang et al., 1995) . The cells were cultured in 96-well plates to minimize the amounts of collectins needed. The plates were seeded with 3610 5 cells in 200 ml RPMI containing 20 % fetal bovine serum. The cells were then inoculated with HIV at an m.o.i. of 0?07. Prior to inoculation the virus was pre-incubated with various concentrations of collectins (or control buffer only) for 30 min at 37 uC. The cells were then maintained in culture in the presence of the same concentration of collectins. Every 3-4 days, 100 ml cell suspension was removed and cell-free supernatants were frozen for use in an HIV-1 p24 antigen assay by ELISA. Fresh media was added with collectin concentrations being maintained by the addition of sufficient amounts of the proteins along with the media. The level of virus replication was assayed by measurement of p24 antigen levels in the supernatant using a p24 antigen ELISA kit obtained from Perkin Elmer Life Sciences, following the manufacturer's instructions. Briefly, 100 ml cell-free supernatants from HIV infected U937 cells were added to assay wells that were coated with mAb specific for the p24 protein of HIV-1. For each assay negative and positive controls were included, and standard curves were obtained through the addition of known amounts of purified p24 antigen. These controls showed consistent results through all the assays, and were within the expected range (according to the manufacturer's instructions). The supernatants and controls were incubated for 2 h at 37 uC. After washing, the plates were incubated for 1 h at 37 uC with biotinylated polyclonal antibodies directed against HIV-1 p24 protein.
Bound antibody was detected by the addition of streptavidin-HRP and OPD substrate solution.
Statistics. Statistical comparisons were made using Student's paired t-test and ANOVA using the Statmost program.
RESULTS
Comparison of the high mannose oligosaccharide attachments of preparations of HIV gp120
As shown in Fig. 1 , HIV BAL and HIV SF2 had extensive high mannose oligosaccharide attachments as assessed by lectin blotting, whereas the deglycosylated form of HIV SF2 had no such attachments. Note also that HIV BAL stained more strongly for high mannose oligosaccharides than HIV SF2 . This difference in glycosylation could reflect either differences in the cell lines used to produce the two preparations or differences in N-linked glycosylation sites on the viral strains.
Recombinant SP-D binds to HIV envelope protein gp120 through its lectin activity
As shown in Fig. 2(a) , RhSP-D dodecamers bound to gp120 of the HIV BAL strain. The binding of RhSP-D to IAV was tested in parallel as a positive control. The binding to gp120 of HIV BAL was approximately equal if the assay was performed without the ethanol and methanol fixation step (data not shown). The binding of SP-D was significantly greater than the binding of BSA, and was abrogated by the addition of mannose or EDTA during the ELISA (Fig. 2b) . The binding of SP-D to gp120 was completely dependent on oligosaccharide attachments on gp120, since it bound strongly to HIV SF2 but not to the deglycosylated preparation HIV SF2deglyc (Fig. 2c) . , and tested their ability to bind to gp120 of HIV (Fig. 3) . High molecular mass native SP-D bound to a significantly greater extent than low molecular mass SP-D to the glycosylated forms of gp120 (HIV BAL and HIV SF2 ). Both forms of native SP-D showed minimal binding to HIV SF2deglyc . Of note, high molecular mass SP-D bound to HIV BAL to a significantly greater degree than to HIV SF2 , perhaps due to the increased presence of high mannose oligosaccharides on HIV BAL . Note that the binding of SP-D to IAV glycoproteins depends on the presence of high mannose oligosaccharides on these proteins as well .
SP-A does not bind to gp120 of HIV
The mechanism of binding of SP-A to IAV differs from that of SP-D, and does not involve recognition of IAV-associated carbohydrates by the lectin activity of SP-A. Instead, SP-A binds to IAV via attachment of the viral haemagglutinin to sialic acids on SP-A (Benne et al., 1995; van Eijk et al., 2003 van Eijk et al., , 2004 . Despite strong binding to IAV, we found no measurable binding of SP-A to gp120 of HIV BAL (mean OD 450 for the binding of 2?5 mg SP-A ml 21 to gp120 was 20?07±0?01 as compared to 0?86±0?26 for the binding to IAV, n=4, P<0?04, background binding to BSA subtracted prior to analysis).
Binding of SP-D to gp120 exceeds the binding of MBL: the role of the CRD
As shown in Fig. 4(a) , RhMBL bound to HIV BAL to an extent comparable to its binding to IAV. The binding to HIV BAL was significantly greater than the binding to HIV SF2 , which in turn exceeded the binding to HIV SF2deglyc , consistent with the previously demonstrated binding of MBL to HIV (or IAV) (Hartshorn et al., 1993) via its CRD. Note again that the relatively greater binding of MBL to HIV BAL , compared to the binding to HIV SF2 , could reflect a lower amount of high mannose oligosaccharides on the latter preparation. The binding of MBL was compared to the binding of SP-D using biotinylated preparations of the collectins (Fig. 4b, c, d) . A comparable extent of biotinylation was confirmed by the similar binding of streptavidin-HRP to equal amounts of the proteins coated directly on ELISA plates (data not shown). SP-D bound significantly more than MBL to HIV BAL or HIV SF2 in these assays. Similar results have been obtained with IAV in prior studies . The binding was measured by ELISA using polyclonal rabbit antibodies directed against SP-D, and the results represent the mean±SEM of three separate experiments using 160 ng ml "1 of the SP-D preparations. The binding of high molecular mass SP-D (mainly composed of dodecamers) to gp120 of HIV BAL and HIV SF2 strains was significantly greater than the binding of low molecular mass SP-D (predominantly composed of trimers) (P<0?001; indicated by **). The binding of high molecular mass form of SP-D to gp120 of HIV BAL was significantly greater than the binding to that of HIV SF2 strains, which in turn was significantly greater than the binding to deglycosylated gp120 of HIV SF2 strain (P values shown). Note that gp120 of HIV BAL had more intense staining for high mannose oligosaccharides than HIV SF2 (Fig. 1) . MM, molecular mass.
the dodecamer fractions of SP-D and SP-D/MBL neck+CRD were used. The SP-D/MBL neck+CRD chimera bound more strongly than either SP-D or MBL. Similar results were obtained when testing binding to IAV (White et al., , 2001 ; data not shown).
The binding of the recombinant collectins was also tested by an alternative method in which the bound collectins were detected by specific mAbs (Fig. 5) . The mAb directed against the CRD of MBL and the mAb directed against SP-D resulted in similar OD 450 values when reacted with equal concentrations of various fractions of SP-D/MBL neck+CRD (for the MBL antibody) and RhSP-D dodecamers (for the SP-D antibody). When testing the binding of the collectins using these antibodies, dodecamers of SP-D/MBL neck+CRD again bound more strongly to gp120 of HIV BAL as compared to dodecamers of SP-D (Fig. 5 ). Higher molecular mass multimers (that contained as many as 32 trimeric CRD heads) and trimers of SP-D/MBL neck+CRD were also tested. The binding of the higher molecular mass multimers to HIV gp120 was not greater than the binding of dodecamers. However, the trimeric fraction of SP-D/MBL neck+CRD bound markedly less than multimers or dodecamers. Thus, the degree of multimerization was a critical determinant of the increased binding activity of SP-D/MBL neck+CRD .
As shown in compare the activities of these collectins using an unrelated assay we tested neutralizing activity vs HIV.
SP-D inhibits infectivity of HIV at significantly lower concentrations than MBL
To determine if the increased ability of SP-D to bind to HIV gp120 is associated with a greater ability to inhibit infectivity of the virus, we utilized a model of infection of the highly susceptible undifferentiated U937 cells. Results of an HIV neutralization experiments are shown in Fig. 6 . A replicate experiment is shown in Table 1 . SP-D caused significant inhibition of HIV replication at concentrations of ¢2 mg ml 21 in both experiments at 3 or 6 days after infection. Although inhibition by SP-D was only partial in this model at the concentrations tested, the results overall were similar to the binding results regarding the comparative activity of SP-D, MBL and SP-D/MBL neck+CRD .
Inhibition was variable at 0?5 and 1 mg SP-D ml
21
. MBL did not cause inhibition of viral growth at the same concentrations (e.g. 0?5-5 mg ml
). However, SP-D/MBL neck+CRD significantly inhibited replication of HIV in U937 cells (Fig. 6, Tables 1 and 2 ). The degree of inhibition caused by SP-D/MBL neck+CRD was greater than that of SP-D at 1 mg ml 21 in both experiments (involving four replicate cultures for each assay condition per experiment). Overall the experiments suggest greater viral inhibition was achieved with SP-D/MBL neck+CRD than with wild-type SP-D, although this was not seen at all concentrations tested. Inhibition by SP-D/MBL neck+CRD became more pronounced after increased time in culture as shown in Table 2 in which experiments were carried out to 11 days in culture. Even at day 11 no consistent effect of MBL was obtained. Hence replacement of the N-terminus and collagen domain of MBL with those of SP-D significantly increased the neutralizing activity of MBL (as we have observed for IAV previously).
DISCUSSION
HIV undergoes rapid mutation allowing it to evade adaptive host defence responses. Nevertheless, some subjects are resistant to infection with HIV or to progression of HIVrelated disease after infection. Recent studies indicate that innate host defence mechanisms contribute to susceptibility or resistance to HIV infection. In this paper, SP-D is demonstrated to have significant HIV-binding and -inhibitory activities that exceed those of MBL. Recent discoveries that SP-D is expressed in various mucosal locations, like the oral cavity and the female genital tract (Leth-Larsen et al., 2004; Madsen et al., 2000) , indicate that SP-D may play a role during sexual or vertical transmission of HIV. Levels in BAL fluids are between 135 and 880 ng ml 21 with concentrations in situ in the lung being considerably higher than this (Wright, 1997) . Hence, levels of SP-D in BAL fluids should inhibit virus replication based on our findings. This is potentially important since HIV can be isolated from BAL fluid and alveolar macrophages appear to be an important site of HIV replication in advanced HIV disease (Hoshino et al., 2002; Nakata et al., 1997) . SP-D levels in blood (e.g. 158 and 3711 ng ml
21
; Husby et al., 2002; Leth-Larsen et al., 2005) are sufficient to bind to, and in some cases to inhibit replication of, HIV. Levels in blood and multimerization of SP-D are determined strongly by genetic factors. Hence, the genotype of SP-D could influence susceptibility or progression of HIV infection. This hypothesis is supported by our finding of a differential ability of high and low molecular mass native SP-D to bind to gp120. For viral neutralization assays, we chose to test concentrations of SP-D similar to those found in blood or unconcentrated BAL fluids. At these concentrations inhibition of infectivity of HIV was only partial, whereas similar concentrations fully inhibit infectivity of IAV . The reasons for this discrepancy are unclear, although it is possible that SP-D-bound HIV can still enter and infect U937 cells to a reduced extent. The rationale for choosing U937 cells was to avoid known effects of SP-D on activation and proliferation of peripheral blood lymphocytes, which could be confounding (Borron et al., 1998) . In addition, the most likely site of HIV replication in the lung or other mucosal sites would be macrophages so that macrophage like cells should be more relevant for our studies. It will, of course, also be of great interest to study the effects of SP-D on HIV infection of lymphocytic cells. In any case our current results show that SP-D can exert suppressive effects on HIV replication in macrophage-like cells. This may be significant in vivo because alveolar macrophages may be an important reservoir of infection in advanced HIV disease (Hoshino et al., 2002) . It will also be important to determine if SP-D can inhibit replication of primary isolates of HIV and macrophage-tropic strains since results may differ from those obtained with HIV LAI (Saifuddin et al., 2000) .
The mechanism of binding of SP-D to HIV gp120 (i.e. calcium dependent attachment to N-linked sugars) resembles its binding to various other microbial ligands, including IAV (for which SP-D plays a key role in host defence; Hartshorn et al., 1994; Hawgood et al., 2004; LeVine et al., 2001; Reading et al., 1997) . Notably, SP-D shows a higher apparent affinity for HIV gp120 than MBL. Using the SP-D/ MBL neck+CRD chimera we demonstrated that the greater binding activity of SP-D is not the result of differences in the binding affinity of the CRD domain of SP-D, since the SP-D/ MBL neck+CRD chimera also bound more strongly than MBL. The experiments were performed as in Table 1 except that the cells were maintained in culture for 11 days after infection. Very similar results were obtained in studies of influenza viruses .
The greater binding activity of SP-D compared to MBL must then result from differences in the N-terminal and collagen domains of the molecule, or associated differences in the number or spatial distribution of CRDs. (Hartshorn et al., 2002; White et al., 2000 White et al., , 2001 . In these studies the enhanced viral-binding and -aggregating activity of SP-D was also dependent on higher order multimerization of the molecule. Trimeric forms of SP-D had reduced binding activity and lacked viral aggregating activity in prior studies (BrownAugsburger et al., 1996; White et al., 2000 White et al., , 2001 . The finding in this paper of the reduced binding to gp120 by predominantly trimeric low molecular mass native SP-D is, therefore, consistent with prior results.
We used two different methodologies to assess relative binding of the collectins (i.e. biotinylation of the collectins, and detection with anti-SP-D or anti-MBL antibodies) with similar results. Furthermore, the relative binding paralleled findings with influenza virus. Hence, the overall conclusion that SP-D and SP-D/MBL neck+CRD have stronger binding to HIV gp120 than MBL seems well supported. The relative binding activity of these collectins also correlated with their ability to inhibit replication of HIV.
Previous studies have demonstrated that MBL inhibits HIV replication in culture, although the concentrations needed to achieve neutralization were relatively high (e.g. partial inhibition at 20-30 mg ml
) (Ezekowitz et al., 1989; Hart et al., 2003) . Hence, the failure to demonstrate inhibition of HIV replication by MBL at the doses used in our study is consistent with other observations. The ability of MBL to fix complement on HIV-infected cells could be important to its in vivo activity (Haurum et al., 1993) . Also, the collectins could promote uptake of viruses by phagocytic cells, which could be important in vivo aside from neutralizing activity (Hartshorn et al., 1996b (Hartshorn et al., , 1997 (Hartshorn et al., , 1998 Ying et al., 2004) . Recent studies have demonstrated that various components of the innate immune system have important interactions with the adaptive immune system (Borron et al., 2002; Brinker et al., 2001) . Furthermore, SP-D has important roles in regulating oxidant and phospholipid metabolism in the lung, and the clearance of apoptotic cells (Clark et al., 2002; Wert et al., 2000) . It is possible that the ability of SP-D to bind to HIV could affect the presentation of HIV antigens to dendritic cells, or that its other immunoregulatory and homeostatic activities could affect adaptive immune responses in the context of HIV infection. Future studies are needed to address whether SP-D modulates phagocyte uptake of HIV. Such an effect could contribute to containment of HIV in vivo or even facilitate infection (e.g. as in the case of DC-Sign; Spear et al., 2003) .
